Outcomes in AYAs treated in fully pediatric or pediatric-inspired trials (N > 50)
| Trial . | N of patients . | Age range, y . | Median age, y . | CR, % . | Early death, % . | Death in CR, % . | HSCT, % . | EFS/DFS/CRD . | OS . | Reference . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Y . | % . | Y . | % . | |||||||||
| PETHEMA ALL-96 | 81 | 15-30 | 20 | 98 | 1 | 1* | 0* | 6 | EFS, 61 | 6 | 69 | 56 |
| HOVON (FRALLE 93) | 54 | 17-40 | 26 | 91 | 4 | NR | 35 | 2 | EFS, 66 | 2 | 72 | 94 |
| FRALLE 2000 | 89 | 15-29 | 19 | 99 | NR | NR | 28 | 5 | EFS, 61 | 5 | 66 | 95 |
| JALSG ALL202-U | 139 | 16-24 | 19 | 94 | 5 | 4 | 15 | 5 | DFS, 67 | 5 | 73 | 57 |
| Intergroup C10403 | 296 | 17-39 | 24 | NR | NR | NR | NR | 2 | EFS, 66 | 2 | 78 | 58 |
| DFCI 01-175 | 74 | 18-50† | 28† | 86 | 1 | NR | 21 | 4 | EFS, 58 | 4 | 67 | 52 |
| A-BFM (MDACC) | 106 | 13-39 | 22 | 93 | 1 | 8 | 10 | 3 | CRD, 70 | 5 | 60 | 59 |
| HyperCVAD (MDACC) | 102 | 15-40 | 27 | 98 | 1 | 7 | 6 | 3 | CRD, 67 | 5 | 60 | 59 |
| Modified DFCI 91-01‡ | 42 | 18-35 | NR | 98 | 0 | NR | NR | 3 | DFS, 77 | 3 | 83 | 53 |
| GMALL 07/03‡ | 887 | 15-35 | NR | 91 | 4 | NR | 43 | 5 | CRD, 61 | 5 | 65 | 54 |
| GRAALL-2003/2005‡ | 502 | 15-35 | 24 | 97 | NR | NR | NR | 5 | EFS, 59 | 5 | 65 | 96 |
| NOPHO 2008 | 221 | 18-45 | NR | NR | 1 | 6 | NR | 5 | EFS, 74 | 5 | 78 | 4 |
| Trial . | N of patients . | Age range, y . | Median age, y . | CR, % . | Early death, % . | Death in CR, % . | HSCT, % . | EFS/DFS/CRD . | OS . | Reference . | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Y . | % . | Y . | % . | |||||||||
| PETHEMA ALL-96 | 81 | 15-30 | 20 | 98 | 1 | 1* | 0* | 6 | EFS, 61 | 6 | 69 | 56 |
| HOVON (FRALLE 93) | 54 | 17-40 | 26 | 91 | 4 | NR | 35 | 2 | EFS, 66 | 2 | 72 | 94 |
| FRALLE 2000 | 89 | 15-29 | 19 | 99 | NR | NR | 28 | 5 | EFS, 61 | 5 | 66 | 95 |
| JALSG ALL202-U | 139 | 16-24 | 19 | 94 | 5 | 4 | 15 | 5 | DFS, 67 | 5 | 73 | 57 |
| Intergroup C10403 | 296 | 17-39 | 24 | NR | NR | NR | NR | 2 | EFS, 66 | 2 | 78 | 58 |
| DFCI 01-175 | 74 | 18-50† | 28† | 86 | 1 | NR | 21 | 4 | EFS, 58 | 4 | 67 | 52 |
| A-BFM (MDACC) | 106 | 13-39 | 22 | 93 | 1 | 8 | 10 | 3 | CRD, 70 | 5 | 60 | 59 |
| HyperCVAD (MDACC) | 102 | 15-40 | 27 | 98 | 1 | 7 | 6 | 3 | CRD, 67 | 5 | 60 | 59 |
| Modified DFCI 91-01‡ | 42 | 18-35 | NR | 98 | 0 | NR | NR | 3 | DFS, 77 | 3 | 83 | 53 |
| GMALL 07/03‡ | 887 | 15-35 | NR | 91 | 4 | NR | 43 | 5 | CRD, 61 | 5 | 65 | 54 |
| GRAALL-2003/2005‡ | 502 | 15-35 | 24 | 97 | NR | NR | NR | 5 | EFS, 59 | 5 | 65 | 96 |
| NOPHO 2008 | 221 | 18-45 | NR | NR | 1 | 6 | NR | 5 | EFS, 74 | 5 | 78 | 4 |
A-BFM, augmented BFM; CRD, CR duration; DFCI, Dana-Farber Cancer Institute; DFS, disease-free survival; FRALLE, French Acute Lymphoblastic Leukemia Study Group; GMALL, German Multicenter Trials for Adult ALL; HOVON, Hemato-Oncologie voor Volwassenen Nederland; JALSG, Japanese Acute Leukemia Study Group; MDACC, MD Anderson Cancer Center; NR, not reported; PETHEMA, Programa Español de Tratamientos en Hematología.
Including 14 additional Ph+ patients.
Results for AYA subgroup only.
Standard risk only; no HSCT.